Phosphoserine phosphatase (PSPH), whose role in lung cancer has already been explored [99], shows a relatively high percentage of alteration in the prostate cancer cohort, up to 11% of the specimens, mostly due to gene overexpression (except for a few cases in which the gene is deleted). The gene discussed is PSPH; the disease is lung carcinoma.